Literature DB >> 21540732

Effect of preoperative magnetic resonance imaging diagnosis of osteomyelitis on the surgical management and outcomes of pressure ulcers.

Lily N Daniali1, Kari Keys, David Katz, David W Mathes.   

Abstract

Despite advances in imaging technology, it is unclear whether preoperative MRI diagnosis of osteomyelitis influences surgical management and improves surgical outcome. The purpose of this retrospective study was to determine whether preoperative diagnosis of osteomyelitis by pelvic MRI influenced the surgical management of pressure sores and flap outcomes. The characteristics, pre- and intraoperative management, and surgical outcomes of the most recent flap surgery in 2 groups were compared: 26 patients diagnosed with osteomyelitis by preoperative MRI and 21 patients diagnosed by culture growth from an intraoperative bone specimen postoperatively. Patients with osteomyelitis diagnosed by MRI had 10 ulcer recurrences at the same site (39%) versus 6 (29%) among patients with osteomyelitis diagnosed by bone culture (odds ratio = 2.4, P = 0.22). We found that patients with a diagnostic preoperative MRI did not differ significantly in rates of antibiotic administration, ostectomy, dehiscence, revision, or infection.

Entities:  

Mesh:

Year:  2011        PMID: 21540732     DOI: 10.1097/SAP.0b013e3181fec647

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  3 in total

1.  Pressure sores.

Authors:  Sachin M Shridharani; Howard D Wang; Justin M Sacks
Journal:  Eplasty       Date:  2013-01-21

2.  Pressure Ulcer-Related Pelvic Osteomyelitis: A Neglected Disease?

Authors:  Phani Bodavula; Stephen Y Liang; Jiami Wu; Paige VanTassell; Jonas Marschall
Journal:  Open Forum Infect Dis       Date:  2015-08-06       Impact factor: 3.835

3.  Combined V-Y Fasciocutaneous Advancement and Gluteus Maximus Muscle Rotational Flaps for Treating Sacral Sores.

Authors:  Hyun Ho Han; Eun Jeong Choi; Suk Ho Moon; Yoon Jae Lee; Deuk Young Oh
Journal:  Biomed Res Int       Date:  2016-06-06       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.